header logo image


Page 215«..1020..214215216217..220230..»

Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung…

February 14th, 2021 7:12 pm

ELK CITY, Idaho, Feb.10, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today acquisition of the JadiCell, cell therapy, for use in the treatment of acute respiratory distress syndrome and other lung pathologies.

"Having worked with the Team at Therapeutic Solutions International for over 4 years, I am glad to place our highly promising and clinically advanced stem cell therapy into this innovative and cutting-edge company," said Dr. Amit Patel, inventor of the JadiCell. "Therapeutic Solutions International is unique in that it is currently running clinical trials in the area of nutraceuticals, as well as developing preclinical and clinical stage immunotherapies. There are numerous synergies to be had with the existing work and expertise in the Company."

"While there is a lot of excitement about various approaches to lung inflammation, there are very few therapies that not only potently block pathological immunity while concurrently induce regeneration of pulmonary tissues," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To date, by far the most promising regenerative therapy our scientists have worked with for acute respiratory distress syndrome (ARDS) has been the JadiCell. I am honored to work with our team of experts such as Dr. Francesco Marincola and Dr. Santosh Kesari in leading the JadiCell through Phase III and into the hands of patients."

"It is a significant accomplishment to acquire rights to this extremely promising and cost-effective technology that is scalable and functions as a 'cellular drug,'" said Famela Ramos, Vice President of Business Development. "To our knowledge this is the only stem cell therapy for lung pathologies that does not require animal components and can be generated in sufficient quantities to address the multi-billion-dollar market of ARDS."

"Dr. Patel and his team have been strong collaborators with us since our first licensing deal using the JadiCell for Chronic Traumatic Encephalopathy," stated Timothy Dixon, President and CEO of the Company. "Having worked with these cells, we appreciate that to date they are by far the most effective at production of cytokines, stimulation of regeneration, and inhibition of pathological inflammation. We are extremely confident in our ability to take these cells to the finish line in treatment of end stage lung disease."

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

[emailprotected]

SOURCE Therapeutic Solutions International

Home

The rest is here:
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung...

Read More...

Outlook on the Cell Therapy Global Market to 2027 – Opportunity Analysis and Industry Forecasts – Yahoo Finance

February 14th, 2021 7:12 pm

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Story continues

The study provides an in-depth analysis of the global cell therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.

Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps in understanding the forms and types of cell therapy used across the globe.

Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Topics Covered:

Chapter 1: Introduction1.1. Report Description1.2. Key Benefits for Stakeholders1.3. Key Market Segments1.4. Research Methodology1.4.1. Secondary Research1.4.2. Primary Research1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary2.1. Key Findings of the Study2.2. Cxo Perspective

Chapter 3: Market Overview3.1. Market Definition and Scope3.2. Key Findings3.2.1. Top Player Positioning3.2.2. Top Investment Pockets3.2.3. Top Winning Strategies3.3. Porter'S Five Forces Analysis3.4. Impact Analysis3.4.1. Drivers3.4.1.1. Technological Advancements in the Field of Cell Therapy3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies3.4.1.3. The Rise in Adoption of Regenerative Medicine3.4.2. Restraint3.4.2.1. Developing Stage and Pricing3.4.3. Opportunity3.4.3.1. High Growth Potential in Emerging Markets3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type4.1. Overview4.1.1. Market Size and Forecast4.2. Stem Cell4.2.1. Key Market Trends and Opportunities4.2.2. Market Size and Forecast, by Region4.2.3. Market Size and Forecast, by Type4.2.3.1. Bone Marrow, Market Size and Forecast4.2.3.2. Blood, Market Size and Forecast4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast4.3. Non-Stem Cell4.3.1. Key Market Trends and Opportunities4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type5.1. Overview5.1.1. Market Size and Forecast5.2. Autologous5.2.1. Key Market Trends and Opportunities5.2.2. Market Size and Forecast, by Region5.2.3. Market Analysis, by Country5.3. Allogeneic5.3.1. Key Market Trends and Opportunities5.3.2. Market Size and Forecast, by Region5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area6.1. Overview6.1.1. Market Size and Forecast6.2. Malignancies6.2.1. Market Size and Forecast, by Region6.2.2. Market Analysis, by Country6.3. Musculoskeletal Disorders6.3.1. Market Size and Forecast, by Region6.3.2. Market Analysis, by Country6.4. Autoimmune Disorders6.4.1. Market Size and Forecast, by Region6.4.2. Market Analysis, by Country6.5. Dermatology6.5.1. Market Size and Forecast, by Region6.5.2. Market Analysis, by Country6.6. Others6.6.1. Market Size and Forecast, by Region6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user7.1. Overview7.1.1. Market Size and Forecast7.2. Hospitals & Clinics7.2.1. Key Market Trends and Opportunities7.2.2. Market Size and Forecast, by Region7.2.3. Market Analysis, by Country7.3. Academic & Research Institutes7.3.1. Key Market Trends and Opportunities7.3.2. Market Size and Forecast, by Region7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region8.1. Overview8.2. North America8.3. Europe8.4. Asia-Pacific8.5. LAMEA

Chapter 9: Company Profiles9.1. Allosource9.1.1. Company Overview9.1.2. Company Snapshot9.1.3. Operating Business Segments9.1.4. Product Portfolio9.1.5. Key Strategic Moves and Developments9.2. Cells for Cells9.2.1. Company Overview9.2.2. Company Snapshot9.2.3. Operating Business Segments9.2.4. Product Portfolio9.3. Holostem Terapie Avanzate Srl9.3.1. Company Overview9.3.2. Company Snapshot9.3.3. Operating Business Segments9.3.4. Product Portfolio9.4. Jcr Pharmaceuticals Co. Ltd.9.4.1. Company Overview9.4.2. Company Snapshot9.4.3. Operating Business Segments9.4.4. Product Portfolio9.4.5. Business Performance9.4.6. Key Strategic Moves and Developments9.5. Kolon Tissuegene, Inc.9.5.1. Company Overview9.5.2. Company Snapshot9.5.3. Operating Business Segments9.5.4. Product Portfolio9.5.5. Key Strategic Moves and Developments9.6. Medipost Co. Ltd.9.6.1. Company Overview9.6.2. Company Snapshot9.6.3. Operating Business Segments9.6.4. Product Portfolio9.6.5. Business Performance9.7. Mesoblast Ltd9.7.1. Company Overview9.7.2. Company Snapshot9.7.3. Operating Business Segments9.7.4. Product Portfolio9.7.5. Business Performance9.8. Nuvasive, Inc.9.8.1. Company Overview9.8.2. Company Snapshot9.8.3. Operating Business Segments9.8.4. Product Portfolio9.8.5. Business Performance9.9. Osiris Therapeutics, Inc.9.9.1. Company Overview9.9.2. Company Snapshot9.9.3. Operating Business Segments9.9.4. Product Portfolio9.10. Stemedica Cell Technologies, Inc.9.10.1. Company Overview9.10.2. Company Snapshot9.10.3. Operating Business Segments9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/bja7iz

See the rest here:
Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance

Read More...

Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 – The Courier

February 14th, 2021 7:12 pm

The global stem cell therapy market is expected to witness a CAGR of 10.6% during the forecast period 2019-2024, and is also anticipated to reach USD 214.5 million by 2024. Growing awareness related to the therapeutic potency of stem cells, development of infrastructure related to stem cell banking and processing, development of advanced genome-based cell analysis techniques, and increasing private-public investment for the development of stem cell therapies are driving the growth of the stem cell therapy market.

Get a free copy of sample report: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample

Supportive regulations to drive the growth of the stem cell therapy market

Supporting regulations across developing countries, increasing prevalence of chronic diseases, technological advancement in healthcare, cellular therapies are the major advancements in transforming healthcare and identification of new stem cell lines are also fueling the growth of the stem cell therapy market.

Diseases such as osteoarthritis, multiple sclerosis, heart failure, hearing loss and cerebral palsy are some of the diseases that could be treated using stem cell therapies. For instance, according to the WHO by 2050, it is estimated 900 million people will have disabling hearing loss. Moreover, 60 percent of childhood hearing loss is due to preventable causes.

Allogenic stem cell therapy market to hold the larger share in the market

There are two types of stem cell therapy, allogeneic and autologous. Of both, allogenic segment account for the larger share and is also predicted to grow at the faster rate in the coming years in the market due to its extensive therapeutic applications, increasing commercialization of allogeneic products, easy production scale-up process, and growing number of clinical trials related to allogeneic therapies.

The stem cell therapy market has been segmented by therapeutic application into gastrointestinal diseases, musculoskeletal disorders, surgeries, cardiovascular diseases, and wound and injuries. Musculoskeletal disorders category contributed the largest revenue in the market due to increasing prevalence of musculoskeletal disorders and bone & joint diseases, increasing availability of stem cell-based products for the treatment of musculoskeletal disorders, and growing patient preference for effective & early treatment strategies.

Do you have any specific research requirement? Ask for customization: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report

The global stem cell therapy market has also been segmented by cell source into adipose tissue-derived mesenchymal stem cell, cord blood cells and bone marrow-derived mesenchymal stem cells. Of all the categories, the bone marrow-derived mesenchymal stem cells are increasingly being used for therapeutic applications.

North America offers huge opportunities for stem cell therapy industry players

The North American stem cell therapy market will remain the largest during the forecast period. The region is further predicted to observe the fastest growth during the forecast period in the global market owing to technological upgradation and large capital invested in the research and development activities. Moreover, increasing number of clinical trials to evaluate therapeutic potential of products, increasing prevalence of chronic diseases, the growing patient base for target diseases, growing public awareness related to the therapeutic potency of therapy, and increasing public-private funding & research grants for developing safe and effective stem cell therapy products are also supporting the growth of the North American stem cell therapy market.

Investing in research and development is the key strategy adopted by the market players

Major players in the industry are investing in the development of innovative and new products, which is strengthening their position in the stem cell therapy market. In February 2018, MEDIPOST announced that FDA has approved its stem cell-based Alzheimers disease drug, NEUROSTEM for clinical trials. Similarly, in March 2017, Osiris Therapeutics launched Prestige Lyotechnology, a method for storage of living cells and tissues.

Some of the key players operating in the stem cell therapy industry are Osiris Therapeutics, Inc., RTI Surgical, Inc., MEDIPOST Co., Ltd., Nuvasive, Inc., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosource.

More from VynZ Research

Global Stem Cell Banking Market Analysis and Forecast to 2024

The global stem cell banking market is growing at a CAGR of 9.1% during the forecast period reaching USD 10.5 billion by 2024, due to the development of novel technologies of storage, preservation and processing. Stem cell banking is the method of accumulating cord blood, extorting and cryogenically freezing its stem cells for forthcoming use. Cord blood stem cells are used for treating blood diseases such as sickle cell disease, leukemia, and thalassemia. The global stem cell banking market is growing at a significant rate due to the development of novel technologies of storage, preservation and processing. The market has witnessed a high demand for placenta stem cells over the last few years, due to the increasing public awareness regarding the therapeutic prospective of stem cells.

Explore more at: https://www.vynzresearch.com/healthcare/stem-cell-banking-market/request-sample

Global Protein Expression Market Analysis and Forecast to 2024

The global protein expression market was evaluated at USD 1,873.1 million in 2018. The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression industry is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.

Explore more at: https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample

U.S. Protein Expression Market Analysis and Forecast to 2024

The U.S. protein expression market is expected to grow at a CAGR of 11.6% during the forecast period with its market size predicted to reach USD 1.2 billion by 2024. The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country. Prokaryotic expression systems and mammalian cell expression systems are the major contributors to the protein expression industry in the region.

Explore more at: https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample

Contact Us:

VynZ Research

Call: +91-996-028-8381

Toll Free (U.S. and Canada): +1-888-253-3960

Email: enquiry@vynzresearch.com

Connect with Us: LinkedIn | Facebook | Twitter

Go here to see the original:
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier

Read More...

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning…

February 14th, 2021 7:11 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.

Magenta continues to generate encouraging data across our pipeline, furthering our commitment to patients to expand eligibility and improve the clinical outcomes with stem cell transplant, said John Davis Jr., M.D., M.P.H., M.S., Magentas Head of Research & Development and Chief Medical Officer. Our presentations this year at TCT highlight the potential wide-ranging utility of our portfolio, and we are particularly excited to share these results, and to continue our progress in the year ahead.

Oral Presentations Showcasing Clinical Data of MGTA-145 Stem Cell Mobilization Program

Magenta is developing MGTA-145 in combination with plerixafor utilizing complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation. This combination has the potential to be the preferred mobilization regimen for rapid, reliable, predictable and safe collection of high numbers of functional blood stem cells to improve outcomes across autologous and allogeneic stem cell transplantation, which also includes stem cells necessary for all HSC-based gene therapies.

Title: MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)Presenting Author: Chang Li, Ph.D., Division of Medical Genetics, Department of Medicine, University of WashingtonDate and Time of Presentation: Session B Transplantation for Non-Malignant Disease; Monday, February 8, 2021, 3:15PM CST / 4:15PM EST

Data from this preclinical study demonstrate the potential of MGTA-145 plus plerixafor to serve as an efficient, single-dose mobilization regimen for in vivo HSC gene therapy where stem cells could be gene corrected or edited without having to remove them from the body. This could potentially replace current mobilization regimens that rely on ex vivo gene therapy approaches to treat genetic diseases.

Title: MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)Presenting Author: Kevin Goncalves, Ph.D., Magenta TherapeuticsDate and Time of Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 4:00PM CST / 5:00PM EST

Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. MGTA-145 plus plerixafor mobilized high numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models.

Oral Presentation Showcasing Preclinical Study of MGTA-117 Targeted ADC Conditioning Program

Magenta is developing a suite of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magentas targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based treatments. These programs focus on developing targeted products that remove specific cell types, with an approach that is tailored to the patients disease and transplant requirements.

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted ADC designed to precisely deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant, and to support long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown to be highly selective with potent activity, efficacy and tolerability in preclinical models.

Title: A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)Presenting Author: Leanne Lanieri, M.S., Magenta TherapeuticsDate and Time of Presentation: Session H Novel Conditioning Regimens & Transplantation for Aged Populations, Wednesday, February 10, 2021, 4:00PM CST / 5:00PM EST

Hematopoietic stem cell transplant (HSCT) can often be a curative treatment for patients with acute myeloid leukemia (AML). There is currently a need for safer and more effective targeted conditioning agents, as current conditioning regimens are associated with severe toxicities and high post-transplant relapse or graft failure. MGTA-117 was studied in multiple human leukemic xenograft murine models to mimic untreated and refractory AML. In preclinical models, MGTA-117 significantly increased median survival versus a multi-day standard-of-care regimen using cytarabine. Data from this study demonstrate MGTA-117s potential as a potent, targeted HSCT conditioning agent with anti-leukemic activity, emphasizing its potential to improve HSCT outcomes in AML by reducing the risk of post-transplant relapse.

Poster Presentation Highlighting Preclinical Data of CD45-ADC Targeted Conditioning Program

Magentas other ADC-based conditioning program, CD45-ADC, targets both patient HSCs and disease-causing immune cells. The programs lead target is CD45, a cell surface molecule broadly expressed throughout the hematopoietic and immune systems. CD45-ADC has the potential to significantly increase the number of patients eligible to receive a stem cell transplant, particularly those patients with autoimmune diseases and acute leukemias.

Developing a broad targeting approach for safer patient conditioning prior to HSCT could bring the curative potential of allogeneic HSCT to more patients with both malignant and non-malignant disorders. Current conditioning regimens limit accessibility of this procedure due to toxicity.

Title: Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (AML) (Poster #242)Lead Author: Sharon Hyzy, M.S., Magenta Therapeutics

Data from this study showed conditioning with single agent CD45-ADC enabled complete chimerism in a full mismatch allogeneic HSCT model.

Oral Presentation of MGTA-456 Stem Cell Therapy Expansion Program in Patients with Blood Cancer

Magenta is continuing long-term patient follow up to evaluate MGTA-456 in blood cancers through the investigator-initiated Phase 2 trial in blood cancers at the University of Minnesota and will assess best next steps for the program. Magenta previously announced in June 2020 it had discontinued enrollment in the Phase 2 trial of MGTA-456 in patients with inherited metabolic disorders.

Title: MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-Versus-Host Disease in Adults with High-Risk Hematologic Malignancies (Oral Abstract, #31)Presenting Author: Heather Stefanski, M.D., Ph.D., Assistant Professor, Department of Pediatrics, University of MinnesotaDate and Time of Oral Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 3:00PM CST / 4:00PM EST

Twenty-two patients were enrolled in the study, with 18 transplanted with MGTA-456. Compared to transplant patients who had undergone the same conditioning, GvHD prophylaxis and supportive care, patients who received MGTA-456 showed faster neutrophil recovery (median of 17 days compared to 23 days) and better platelet recovery (median 36 days compared to 59 days). Additionally, incidence of grade 2-4 acute GvHD was lower (24% compared to 46%), likely because of the ability to find a better matched cord unit.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancer, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magentas future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting clinical data, projections regarding our long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our clinical programs, the timing, progress and success of our collaborations, as well as other statements containing words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions that can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from pre-clinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, strategy, goals and anticipated timelines, Magentas ongoing and planned pre-clinical activities, Magentas ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magentas timelines for regulatory submissions and Magentas financial position; and other risks concerning Magenta's programs and operations set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Go here to see the original:
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning...

Read More...

Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi…

February 14th, 2021 7:11 pm

Stem Cell Therapy Market

Stem Cell Therapy Market Projections (2020-2029): The Global market Stem Cell Therapy theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/148234

Prominent players in the industry covered in the report:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Market split by Type, can be divided into:AutologousAllogeneic

Market split by Application, can be divided into:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Market split by Sales Channel, can be divided into:Direct ChannelDistribution Channel

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Therapy marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/148234

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Therapy, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Go here to see the original:
Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi...

Read More...

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2025 FLA…

February 14th, 2021 7:11 pm

MarketQuest.biz presents the intelligent report title as Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 by Company, Type and Application, Forecast to 2025 which depicts valuable insights related to significant market trends driving the industry. The report is designed to meet the readers curiosity and answers some of the most vital questions prevalent in the global market. The market is carefully researched in the report while largely concentrating on numerous growth opportunities worldwide. The report comprises an analysis of key factors including industry manufacturing base, prominent rivals in the business, and business overview. The research study covers necessary factors like prime manufacturers, production worth, key regions, and rate of growth. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

The study provides a detailed review of the industry based on product segments, major applications with the identification largest and fastest-growing products and applications. Our experts have analyzed various companies to understand the products and/services relevant to the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, and expansion strategies have been included in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/6320

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Latest Industry News:

In this report, leading players of the global market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. The report explores the products and applications they concentrate on when operating in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

The study constitutes of key players in the market: Fibrocell Science, Inc., Pluristem Therapeutics Inc, Caladrius Biosciences, Inc., Vericel Corporation, Genzyme Corporation, Dendreon Corporation (Sanpower Group), TiGenix (Takeda), Regeneus Ltd., BrainStorm Cell Therapeutics, U.S. Stem Cell, Inc

Market segment considering production, revenue (value), price trend by type: Autologous Stem Cell Therapy, Non-Stem Cell Therapy

Market segment by consumption growth rate and market share by application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Autoimmune Diseases, Others

Regional segmentation of the market: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

Moreover, market players, shareholders, and other interested parties are the best receivers of trusted insights and strategic advice that the report provides to help them obtain their mission-critical priorities during projected time-period from 2020 to 2025. The extensive range of analyses associates with the impact of these improvements on the future of industry growth. It evaluates the global Autologous Stem Cell and Non-Stem Cell Based Therapies market by segments, by countries, and by manufacturers with revenue share and sales by key countries in these various regions.

ACCESS FULL REPORT: https://www.marketquest.biz/report/6320/global-autologous-stem-cell-and-non-stem-cell-based-therapies-market-2020-by-company-type-and-application-forecast-to-2025

Key Findings of The Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.bizWeb: http://www.marketquest.biz

Read the rest here:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2025 FLA...

Read More...

EU’s refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal – Alliance for Science – Alliance for Science

February 14th, 2021 7:10 pm

Europes refusal to permit its farmers to cultivate genetically engineered (GE) crops led to the avoidable emission of millions of tonnes of climate-damaging carbon dioxide, a new scientific analysis reveals.

The opportunity cost of the EUs refusal to allow cultivation of GE varieties of key crops currently totals 33 million tonnes of CO2 per year, the experts say.

This is equivalent to 7.5 percent of greenhouse gas (GHG) emissions from the entire European agricultural sector, or roughly what might be emitted each year by 10-20 coal-fired power stations.

Given that farmers in North and South America adopted GE crops from the late 1990s onward, this analysis implies that over subsequent decades the additional carbon emitted due to the EUs opposition to genetic engineering will likely be in the hundreds of millions of tonnes.

The findings result from from the fact that GE versions of major crops produce a higher yield because they can better resist damage from insects and competition from weeds.

With Europes farmers condemned to lower total agricultural yields because of GE crop non-adoption, more farmland globally has to be kept in production or plowed up which otherwise might be available for forests to sequester carbon in trees and soil.

The new analysis will make uncomfortable reading for environmental groups that have long combined advocacy for climate mitigation with a steadfast opposition to GMOs because it implies that their opposition to genetic engineering might be substantially worsening the climate emergency.

The paper is co-authored by Emma Kovak and Dan Blaustein-Rejto both from the California-based ecomodernist think tank the Breakthrough Institute and Matin Qaim, from the University of Goettingen, Germany. It is published as a pre-print on the bioRxiv server in advance of formal peer review.

The calculation was made by estimating to what extent GHG emissions could have been avoided if the EUs level of adoption of GE varieties of five major crops (maize, soybean, cotton, canola and sugar beet) in 2017 had been equal to that of the United States.

Our results suggest that GHG emissions reductions from the yield increases in GE crops are substantial and should be included in future analyses, writes lead author Kovak.

The researchers also note that their findings are particularly relevant right now because a possible reassessment of the EUs harsh regulatory regime for biotech crops is currently underway.

However the EUs current policy trend pushes in the opposite direction. As Kovak explains, Europes new Farm-to-Fork Strategy under the European Green Deal aims to expand organic farming, which has lower yields and would be associated with significant increases in global GHG emissions through causing land-use change elsewhere.

She concludes: Rather than offshoring environmental damage to other nations, as the European Green Deal does, the EU should increase agricultural productivity through embracing new crop technologies, thus contributing to global environmental benefits.

The authors, however, caution that their assumptions mean that there are substantial uncertainties in the analysis. They assume, for instance, that increased yields in Europe would lead to a proportionate decrease in production elsewhere.

In reality, while the land-sparing effects of crop yield increases are well established, the magnitude can vary widely according to differing circumstances.

However, uncertainties also mean that the estimated annual GHG savings of 33 million tonnes could on the other hand be a big underestimate. In particular, the analysis does not take into account Europes influence on Africa and Asia, where the EUs refusal to allow farmers to cultivate GE crops has been hugely influential.

Nor does it take into consideration what might have happened if crops more widely grown in Europe than in North America in particular wheat and barley had been genetically engineered to allow similar yield improvements as have been seen in maize, cotton and soy.

At the moment no GE varities of wheat or barley are cultivated widely due to intense and long-standing opposition from politicians and anti-GMO activists. If these crops had been available to farmers in standard GE insect- and weed-resistant varieties, Europes agricultural productivity might have increased substantially.

The researchers conclude on a hopeful note, pointing out that new gene editing technologies will likely further increase the diversity of desirable crop-trait combinations. If these crops are permitted in Europe and elsewhere, huge climate mitigation benefits from future GE crops might still be realized.

Image: European Commission

Follow this link:
EU's refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal - Alliance for Science - Alliance for Science

Read More...

New species of fly named after Singanallur Tank – The Hindu

February 14th, 2021 7:10 pm

A new species of fly, which was recently identified by researchers at the Singanallur Tank, has been named after the water body.

The insect was named Asphondylia singanallurensis in the research paper published in the Zootaxa journal in March 2020. The authors said in the paper that they collected the leaves of jujube shrub (Ziziphus jujuba) growing near the Singanallur Tank during their field visits between 2015 and 2018, that contained leaf galls (abnormal growth on leaves) on the surfaces.

The leaves were dissected in a laboratory and the causative agent for the galls was identified to be a fly from the Cecidomyiidae family, which are commonly known as gall midges. Upon further research which also involved DNA sequencing, the insect was confirmed to be a unique species, according to the research paper.

The paper was authored by Duraikannu Vasanthakumar and Radheshyam M. Sharma from Zoological Survey of India (ZSI) - Western Regional Centre (WRC) in Pune, Senthilkumar Palanisamy from the Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur and Vinny R. Peter from Centre for Urban Biodiversity Conservation and Education (CUBE).

Mr. Vasanthakumar, Senior Zoological Assistant at ZSI - WRC Pune, said there were about 396 different species of flies under the Cecidomyiidae family prior to the discovery of this new species. This particular species has only been reported from Singanallur Tank so far, he told The Hindu on Sunday. Despite the abundance of the jujube shrub (ilanthai in Tamil) in the Western Ghats region, this particular fly has not been reported anywhere so far. Further research regarding the ecological parameters and the life cycle of Asphondylia singanallurensis are being carried out, he noted.

According to Ms. Peter, four more insects have been recently found at Singanallur Tank by researchers and efforts to ascertain whether these are unique species are under way.

In 2017, the Coimbatore Corporation declared the 288-acre Singanallur Tank as a biodiversity conservation zone owing to its rich biodiversity.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

Go here to read the rest:
New species of fly named after Singanallur Tank - The Hindu

Read More...

Son of Monarchs Pays Homage to the Beauty of Migration – Sierra Magazine

February 14th, 2021 7:10 pm

To some, a film about a Mexican scientists spiritual transformation into a butterfly may seem strange. But to Alexis Gambis, its personal. Born to a painter and a filmmaker, Gambis rebelled against a career in art. But after completing a PhD in molecular biology and genetics, he sought ways to bridge his academic research with visual storytelling. I was really drawn to biology from an aesthetic and narrative point of view, Gambis told Sierra.

The result is Son of Monarchs, written and directed by Gambis. It is the recipient of the Alfred P. Sloan Prize, awarded to a feature film focused on science and technology, and recently premiered at the 2021 Sundance Film Festival.

The film follows Mendel (played by Tenoch Huerta), an evolutionary biologist who leaves Mexico for New York to study how the genetic engineering tool CRISPR can alter the physical characteristics of butterflies. After discovering that his grandmother has passed away, Mendel travels to Mexico to attend her funeral in Michoacn, home to the Monarch Butterfly Biosphere Reserve. Whats meant to be a two-day visit reconnects him with old friends and family as well as the trauma that drove him away from the place he once called home.

Much of the film unfolds through flashbacks, blurring the lines between Mendels childhood in Michoacn and his life in New York. Son of Monarchs explores Mendels psychic transformation as he reconciles the loss of his parents, the loss of his culture, and ultimately, the loss of himself.

Mendel as a child, played by Kaarlo Isaacs. | Photo courtesy of Sundance Institute/Alexis Gambis

Although Son of Monarchs explores a range of ideas, Gambis weaves them together with subtle precision. The film is layered with sharp observations on science, spirituality, the environment, and migration. The butterfly migrations of Mendels childhood are diminished by deforestation and mining, even as local schoolchildren memorize and reenact the passage of the monarchs from North America to Mexico and perform climate change through folklore dance (the childrens reenactment is based on a real performance that Gambis saw while in Mexico). As the director, I don't want to take a stance and say, Stop destroying the butterfly forest!" Gambis said. I don't want to preach, because I feel that these conversations are so complicated.

In the film, science and spirituality are not juxtaposed but in conversation with one another. When Mendel embraces his animal spirit during an ancestral ceremony or gazes into his microscope to extract butterfly pigment, the goal of understanding the world is the same.

The film conveys the mundanity of lab work without downplaying its wonder. Oftentimes, scientific pursuit and research are separated from the spiritual aspect, Gambis said. But I feel like they're very much connected. The idea of being in a laboratory and trying to understand the building blocks of life and how things work is the utmost kind of spiritual process.

Son of Monarchs avoids the dramatization of planetary disruption thats common in the science fiction genre (think Snowpiercer, Annihilation, and The Martian). There's this obsession with sensationalizing science where it brings you into these dystopian worlds, Gambis said. I love those films, but I feel like there needs to be room for other types of film where the science is the backdrop.... I don't want the character to suddenly say, Oh, I made a discovery! I would rather watch him work in the lab in silence. It's part of who he is. He doesn't need to speak about it.

Just as science is innate to Mendel, so is his hybrid identity as a Latino immigrant living in between cultures. The film expands the definition of what it means to be an immigrant by deviating from reductive tropes of Latin American migration, like the sacrificial immigrant who risks it all for a better life. What you see in films about Latinos and Mexicans is very stereotypical, Gambis said. "It's usually about crossing the border. And here, it's about Mexican scientists who actually return to Mexico and live between worlds."

Mendel talks butterflies with his girlfriend (played by Alexia Rasmussen) in New York City. | Photo courtesy of Sundance Institute/Alexis Gambis

If you go to a research lab today, it's full of people from around the world that come and migrate for work reasons, Gambis said. It's a different type of migration that happens in the US. Mendels story is an intimate look into the emotional consequences that follow a sovereign choice, and its his negotiation between identity and belonging that makes this film so visceral.

Gambis hopes that viewers walk away from Son of Monarchs with a deeper appreciation of how we are all animals, not only within a specific ecosystem but also as creatures who are as dependent on migration as other species. As a Brooklyn-based immigrant who wrestles with the paradox of cultural belongingtorn between his French, Venezuelan, and American identitieshe encourages the audience to think critically about who they are and where they come from.

I hope people understand that migration is fluid, Gambis said. You can leave and come back. Maybe we don't know where Mendel ends up, but he floats like a butterfly. He's in Mexico, hes in New Yorkthere's no permanence. It's all cyclical. Of course, it's a certain type of migration, because there are some [migrants] that can't go back home. But I want to emphasize that in the animal world, migration is cyclical, and I hope people can relate to that, and to embrace that migration is beautiful.

More:
Son of Monarchs Pays Homage to the Beauty of Migration - Sierra Magazine

Read More...

Podcast: TIME’s 2020 Kid of the Year, Gitanjali Rao – All Together – Society of Women Engineers

February 14th, 2021 7:10 pm

Get ready to be inspired by our latest SWE podcast with TIMEs 2020 Kid of the Year, Gitanjali Rao. Interviewed by the likes of Angelina Jolie and Ellen DeGeneres, Gitanjali has become quite the starand for good reason. At just 15 years old, this brilliant young innovator has designed and built technology and tools that address serious issues like water contamination, opioid addiction and cyberbullying.

Find our SWE Diverse podcasts on SoundCloud, iTunes, Apple Podcasts and more.

Get to know Gitanjali and her innovations in this SWE Diverse episode, hosted by SWE 2020 Achievement Award recipient Jayshree Seth, chief science advocate at 3M. We promise, itll leave you feeling inspired and eager to help the world through engineering.

Each and every one of us has the power to change the world.

-Gitanjali Rao

Gitanjali Rao was recognized as Discovery Education 3M Americas Top Young Scientist in 2017 and received an EPA Presidential award for inventing her device Tethysan early lead detection tool. Gitanjali is also the inventor of Epionea device for early diagnosis of prescription opioid addiction using genetic engineering, and Kindlyan anti-cyberbullying service using AI and Natural Language processing.

She was honored asForbes30 Under 30 in Science in 2019 andTIMEs Top Young Innovator for her innovations and STEM workshops she conducts globally, which has inspired over thirty-five thousand students in the last two years across four continents. In her sessions, she shares her own process of innovation that can be used by students all over the world. She is an experienced TED speaker and often presents in global and corporate forums on innovation and the importance of STEM.

She is an author of the book, Young InnovatorsGuide to STEM which will release in March 2021, and was recently honored as Time Kid of the Year 2020 for her community service and innovations.

Jayshree Seth, Ph.D., is a Corporate Scientist for 3M Company, headquartered in St. Paul, Minnesota, USA, where she has worked for over 27 years. She holds 70 patents on a variety of innovations, with several others pending. Dr. Seth uses scientific knowledge, technical expertise, and professional experience to advance science and develop new products. She currently leads applied technology development for sustainable industrial products in 3Ms Industrial Adhesives and Tapes Division. She is also 3Ms first-ever Chief Science Advocate and is charged with communicating the importance of science in everyday life, breaking down barriers, and building excitement around STEM careers. She is very passionate about teaching, coaching, mentoring and is a sought-after speaker, globally, on a multitude of topics such as innovation, leadership, and science advocacy. Dr. Seth has been interviewed in national and international media, and she has featured in 3M brand campaigns and commercials.

Dr. Seth is the fourth woman and first woman engineer to attain the highest technical designation of Corporate Scientist at 3M, as well as induction into the 3M Carlton Society, which honors the very best among the scientific community. She is also a certified Design for Six Sigma Black Belt. At 3M, she has served on the CEO Inclusion Council, chaired the Asian and Asian American Employee Network (A3CTION), and serves on the Womens Leadership Forum (WLF) Technical Chapter. She has received numerous 3M excellence awards and a record-setting number of intrapreneurial grants to drive innovation. She was conferred the 2020 Achievement Award from the Society of Women Engineers (SWE), the 2019 International Women & Technologies Le Tecnovisionarieaward for sustainability, the 2020 Woman of Distinction by Girl Scouts River Valley, the 2018 Distinguished Alumni Award from her alma mater in India, and was also among engineers selected to attend the National Academy of Engineerings (NAE) 14th annual U.S. Frontiers of Engineering symposium.

Dr. Seth grew up in Northern India, in the university town of Roorkee, at the foothills of the Himalayas and on the banks of the River Ganges canal. She holds a B.Tech. in chemical engineering from NIT, Trichy, India, and an M.S. and Ph.D. in chemical engineering from Clarkson University, New York. Jayshree is a member of the Engineering Advisory Council for Clarkson University. Dr. Seth has over 15 journal publications based on her graduate work, co-authoring several with her husband, who also works at 3M. They enjoy extending science, creativity, and innovation into their kitchen. They have two adult children. Dr. Seth enjoys experiencing other cultures and she is also an avid reader, writer and poet.

Read SWEs newest publication, The Heart of Science: Engineering Footprints, Fingerprints, & Imprints, written by Jayshree Seth. InThe Heart of Science, Seth discusses the relationship society has with science and engineering and offers her unique perspective on topics surrounding advocacy, interdisciplinary contexts, thoughtful leadership and inclusive progress. She also leans on her childhood experiences, and those of her children, as source material on the lessons she has learned during her career journey.All proceeds from the sale of the book will support the Jayshree Seth Scholarship for Women of Color in STEM. This scholarshipto be awarded annually by the Society of Women Engineerswill support a woman pursuing an undergraduate or graduate degree in a STEM field.

SWE Blog provides up-to-date information and news about the Society and how our members are making a difference every day. Youll find stories about SWE members, engineering, technology, and other STEM-related topics.

View original post here:
Podcast: TIME's 2020 Kid of the Year, Gitanjali Rao - All Together - Society of Women Engineers

Read More...

Geoengineering: What could possibly go wrong? Elizabeth Kolbert’s take, in her new book – Bulletin of the Atomic Scientists

February 14th, 2021 7:10 pm

Editors note: This story was originally published by Grist. It appears here as part of theClimate Deskcollaboration. Elizabeth Kolbert is a former member of the Science and Security Board of the Bulletin of the Atomic Scientists.

In Australia, scientists collect buckets of coral sperm, mixing one species with another in an attempt to create a new super coral that can withstand rising temperatures and acidifying seas. In Nevada, scientists nurse a tiny colony of one-inch long Devils Hole pupfish in an uncomfortably hot, Styrofoam-molded pool. And in Massachusetts, Harvard University scientists research injecting chemicals into the atmosphere to dim the suns lightand slow down the runaway pace of global warming.

These are some of the scenes from Elizabeth Kolberts new book,Under a White Sky, a global exploration of the ways that humanity is attempting to engineer, fix, or reroute the course of nature in a climate-changed world. (The title refers to one of the consequences of engineering the Earth to better reflect sunlight: Our usual blue sky could turn apale white.)

Kolbert, a New Yorker staff writer, has been covering the environment for decades: Her first book,Field Notes from a Catastrophe, traced the scientific evidence for global warming from Greenland to Alaska; her second,The Sixth Extinction, followed the growing pace of animal extinctions.

Under a White Skycovers slightly different ground. Humanity is now, Kolbert explains, in the midst of the Anthropocenea geologic era in whichweare the dominant force shaping earth, sea, and sky. Faced with that reality, humans have gotten more creative at using technology to fix the problems that we unwittingly spawned: Stamping out Australias cane toad invasion with genetic engineering, for example, or using giant air conditioners to suck carbon dioxide out of air and turn it into rock. As Kolbert notes, tongue-in-cheek: What could possibly go wrong?

This interview has been condensed and lightly edited for clarity.

Osaka:Under a White Skyis about a lot of things rivers, solar geoengineering, coral reefs but its also about what nature means in our current world. What got you interested in that topic?

Kolbert: All books have complicated births, as it were. But about four years ago, I went to Hawaii to report on a project that had been nicknamed the super coral project. And it was run by a very charismatic scientist namedRuth Gates, who very sadly passed away about two years ago. We have very radically altered the oceans by pouring hundreds of billions of tons of carbon dioxide into the airand we cant get that heat out of the oceans in any foreseeable timescale. We cant change the chemistry back. And if we want coral reefs in the future, were going to have to counter what weve done to the oceans by remaking reefs so they can withstand warmer temperatures. The aim of the project was to see if you could hybridize or crossbreed corals to get more vigorous varieties.

This ideathat we have to counteract one form of intervention in the natural world (climate change) with another form of intervention (trying to recreate reefs)just struck me as a very interesting new chapter in our long and very complicated relationship with nature. And once I started to think about it that way, I started to see that as a pretty widespread pattern. Thats really what prompted the book.

Osaka: Some of these human interventions to save nature seem hopeful and positiveand others go wrong in pretty epic ways. How do you balance those two types of stories?

Kolbert: The book starts with examples that probably will strike many readers as Okay, that makes sense. That makes sense. But it goes from regional engineering solutions through biotechnology, through gene editing, and all the way up to solar geoengineering. So it kind of leads you down what we might call a slippery slope. And one of the interesting things about these cases is that they will divide up people differently. Even people who consider themselves environmentalists will come down on different sides of some of these technologies. The bind were in is so profound that theres no right answer.

Osaka: So someone who accepts what were doing to save the Devils Hole pupfish might not necessarily accept gene-editing mosquitos or dimming the sun through solar geoengineering.

Kolbert: Exactly. And I think sometimes those linesseemclearer than they are once you start to think about it.

Osaka: At one point in the book, theres a quote that is (apocryphally) attributed to Einstein: We cannot solve our problems with the same thinking we used when we created them. But you dont say whether you agree with that sentiment or not. Is that on purpose?

Kolbert: Yeah, you can read the book and say, Im really glad people are doing these things, and I feel better. Or you can read the book and say, as one scientific quote does, This is a broad highway to hell. And both of those are very valid reactions.

Osaka: When you write about geoengineering, you point out that many scientists conclude that its necessary to avoid catastrophic levels of warming, but that it could also be a really bad ideKolbert Do you think that in 15 or 20 years youll be writing about a geoengineering experiment gone wrong, much as youre writing now about failed attempts to protect Louisiana from flooding?

Kolbert: I might argue about the timescales. Im not sure Ill be reporting on it in 15 years, but I thinkyoumight be reporting on it in 30 years.

At the moment, its still the realm of sci-fi, and Im not claiming to have any particular insight into how people are going to respond in the future. But the case thats made in the book by some very smart scientists is that we dont have very many tools in our toolbox for dealing with climate change quickly, because the system has so much inertia. Its like turning around a supertanker: It takes literally decades, even if we do everything absolutely right.

Osaka: Youve reported on climate change for a long time. How does it feel to see geoengineering being explored as a more valuableand potentially necessaryoption?

Kolbert: Well, one thing I learned in the course of reporting the book was that what we now refer to as geoengineering was actually the very first thing that people started to think about when they first realized we were warming the climate. The very first report about climate change that was handed to Lyndon Johnson in 1965 wasnt about how we should stop emittingit was: Maybe we should find some reflective stuff to throw into the ocean to bounce more sunlight back into space!

Its odd, its kind of almost freakish, and I cant explain it, except to say that it sort of fits the pattern of the book.

Osaka: Theres been a longstanding fight in environmentalism between a technology-will-save-us philosophy and a return-to-nature philosophy. Based on the reporting in this book, do you think that the technology camp has won?

Kolbert: I think the book is an attempt to take on both of those schools of thought. On some level, technologyhaswoneven people who would say dont do geoengineering still want to put up solar panels and build huge arrays of batteries, and those are technologies! But where does that leave us? It goes back to Ruth Gates and the super coral project. There was a big fight among coral biologists about whether a project like that should even be pursued. The Great Barrier Reef is the size of Italyeven if you have some replacement coral, how are you going to get them out on the reef? But Gatess point was, were not returning. Even if we stopped emitting carbon dioxide tomorrow, youre not getting the Great Barrier Reef back as it was in a foreseeable timeframe.

My impulse as an old-school environmentalist is to say Well, lets just leave things alone. But the sad fact is that weve intervened so much at this point that evennot intervening is itself an intervention.

Osaka: Now that we have a US president who takes climate change seriously, do you think we could actually start cutting carbon emissions quickly

Kolbert: I really do want to applaud the first steps that theBiden administration has taken. I think they show a pretty profound understanding of the problem. But the question, and its a big one, is What are the limits? Will Congress do anything? What will happen in theSupreme Court? The United States is no longer the biggest emitter on an annual basis, but on a cumulative basis were still the biggest. And we still dont have resolution on how much carbon dioxdie we can put up there to avoid 1.5 or 2 degrees Celsius (3.6 degrees Fahrenheit) of warming. Those are questions with big error bars. If were lucky, I think we can avoid disastrous climate change. But if were not lucky, were already in deep trouble.

Osaka: Is there anything else you want to say about the book?

Kolbert: It sounds kind of weird after our conversation, but the book was actually a lot of fun to write. It sounds odd when youre talking about a book where the subject is so immensely serious.

Osaka: You mean like when the undergraduates in Australia are tossing each other buckets of coral sperm?

Kolbert: Yes! There is always humor in all these situations. I hope that sense of fun comes through.

See more here:
Geoengineering: What could possibly go wrong? Elizabeth Kolbert's take, in her new book - Bulletin of the Atomic Scientists

Read More...

An Introduction to PCR – Technology Networks

February 14th, 2021 7:10 pm

Polymerase chain reaction (PCR) is a technique that has revolutionized the world of molecular biology and beyond. In this article, we will discuss a brief history of PCR and its principles, highlighting the different types of PCR and the specific purposes to which they are being applied.

In 1983, American biochemist Kary Mullis was driving home late at night when a flash of inspiration struck him. He wrote on the back of a receipt the idea that would eventually grant him the Nobel Prize for Chemistry in 1993. The concept was straightforward: reproducing in a laboratory tube the DNA replication process that takes place in cells. The outcome is the same: the generation of new complementary DNA (cDNA) strands based upon the existing ones.

Mullis used the basis of Sanger's DNA sequencing as a starting point for his new technique. He realized that the repeated use of DNA polymerase triggered a chain reaction resulting in a specific DNA segment's amplification.

The foundations for his idea were laid by a discovery in 1976 of a thermostable DNA polymerase, Taq, isolated from the bacterium Thermus aquaticus found in hot springs.1 Taq DNA polymerase has a temperature optimum of 72 C and survives prolonged exposure to temperatures as high as 96 C, meaning that it can tolerate several denaturation cycles.

Before the discovery of Taq polymerase, molecular biologists were already trying to optimize cyclic DNA amplification protocols, but they needed to add fresh polymerase at each cycle because the enzyme could not withstand the high temperatures needed for DNA denaturation. Having a thermostable enzyme meant that they could repeat the amplification process many times over without the need for fresh polymerase at every cycle, making the whole process scalable, more efficient and less time-consuming.

The first description of this polymerase chain reaction (PCR) using Taq polymerase was published in Science in 1985.2

In 1993, the first FDA-approved PCR kit came to market. Since then, PCR has been steadily and systematically improved. It has become a game-changer in everything from forensic evidence analysis and diagnostics, to disease monitoring and genetic engineering. It is undoubtedly considered one of the most important scientific advances of the 20th century.

The PCR is used to amplify a specific DNA fragment from a complex mixture of starting material called template DNA. The sample preparation and purification protocols depend on the starting material, including the sample matrix and accessibility of target DNA. Often, minimal DNA purification is needed. However, PCR does require knowledge of the DNA sequence information that flanks the DNA fragment to be amplified (called target DNA).

From a practical point of view, a PCR experiment is relatively straightforward and can be completed in a few hours. In general, a PCR reaction needs five key reagents:

DNA to be amplified: also called PCR template or template DNA. This DNA can be of any source, such as genomic DNA (gDNA), cDNA, and plasmid DNA.DNA polymerase: all PCR reactions require a DNA polymerase that can work at high temperatures. Taq polymerase is a commonly used one, which can incorporate nucleotides at a rate of 60 bases/second at 70 C and can amplify templates of up to 5 kb, making it suitable for standard PCR without special requirements. New generations of polymerases are being engineered to improve reaction performance. For example, some are engineered to be only activated at high temperatures to reduce non-specific amplification at the beginning of the reaction. Others incorporate a proofreading function, important, for example, when it is critical that the amplified sequence matches the template sequence exactly, such as during cloning.Primers: DNA polymerases require a short sequence of nucleotides to indicate where they need to initiate amplification. In a PCR, these sequences are called primers and are short pieces of single-stranded DNA (approximately 15-30 bases). When designing a PCR experiment, the researcher determines the region of DNA to be amplified and designs a pair of primers, one on the forward strand and one on the reverse, that specifically flanks the target region. Primer design is a key component of a PCR experiment and should be done carefully. Primer sequences must be chosen to target the unique DNA of interest, avoiding the possibility of binding to a similar sequence. They should have similar melting temperatures because the annealing step occurs simultaneously for both strands. The melting temperature of a primer can be impacted by the percentage of bases that are guanine (G) or cytosine (C) compared to adenine (A) or thymine (T), with higher GC contents increasing melting temperatures. Adjusting primer lengths can help to compensate for this in matching a primer pair. It is also important to avoid sequences that will tend to form secondary structures or primer dimers, as this will reduce PCR efficiency. Many free online tools are available to aid in primer design.Deoxynucleotide triphosphates (dNTPs): these serve as the building blocks to synthesize the new strands of DNA and include the four basic DNA nucleotides (dATP, dCTP, dGTP, and dTTP). dNTPs are usually added to the PCR reaction in equimolar amounts for optimal base incorporation.PCR buffer: the PCR buffer ensures that optimal conditions are maintained throughout the PCR reaction. The major components of PCR buffers include magnesium chloride (MgCl2), tris-HCl and potassium chloride (KCl). MgCl2 serves as a cofactor for the DNA polymerase, while tris-HCl and KCl maintain a stable pH during the reaction.The PCR reaction is carried out in a single tube by mixing the reagents mentioned above and placing the tube in a thermal cycler.The PCR amplification consists of three defined sets of times and temperatures termed steps: denaturation, annealing, and extension (Figure 1).

Figure 1: Steps of a single PCR cycle.

Each of these steps, termed cycles, is repeated 30-40 times, doubling the amount of DNA at each cycle and obtaining amplification (Figure 2).

Figure 2: The different stages and cycles of DNA molecule amplification by PCR.

Let's take a closer look at each step.

The first step of PCR, called denaturation, heats the template DNA up to 95 C for a few seconds, separating the two DNA strands as the hydrogen bonds between them are rapidly broken.

The reaction mixture is then cooled for 30 seconds to 1 minute. Annealing temperatures are usually 50 - 65 C however, the exact optimal temperature depends on the primers' length and sequence. It must be carefully optimized with every new set of primers.

The two DNA strands could rejoin at this temperature, but most do not because the mixture contains a large excess of primers that bind, or anneal, to the template DNA at specific, complementary positions. Once the annealing step is completed, hydrogen bonds will form between the template DNA and the primers. At this point, the polymerase is ready to extend the DNA sequence.

The temperature is then raised to the ideal working temperature for the DNA polymerase present in the mixture, typically around 72 C, 74 C in the case of Taq.

The DNA polymerase attaches to one end of each primer and synthesizes new strands of DNA, complementary to the template DNA. Now we have four strands of DNA instead of the two that were present to start with.

The temperature is raised back to 94 C and the double-stranded DNA molecules both the "original" molecules and the newly synthesized ones denature again into single strands. This begins the second cycle of denaturation-annealing-extension. At the end of this second cycle, there are eight molecules of single-stranded DNA. By repeating the cycle 30 times, the double-stranded DNA molecules present at the beginning are converted into over 130 million new double-stranded molecules, each one a copy of the region of the starting molecule delineated by the annealing sites of the two primers.

To determine if amplification has been successful, PCR products may be visualized using gel electrophoresis, indicating amplicon presence/absence, size and approximate abundance. Depending on the application and the research question, this may be the endpoint of an experiment, for example, if determining whether a gene is present or not. Otherwise, the PCR product may just be the starting point for more complex downstream investigations such as sequencing and cloning.

Thanks to their versatility, PCR techniques have evolved over recent years leading to the development or several different types of PCR technology.

Some of the most widely used ones are:

One of the most useful developments has been quantitative real-time PCR or qPCR. As the name suggests, qPCR is a quantitative technique that allows real-time monitoring of the amplification process and detection of PCR products as they are made.2 It can be used to determine the starting concentration of the target DNA, negating the need for gel electrophoresis in many cases. This is achieved thanks to the inclusion of non-specific fluorescent intercalating dyes, such as SYBR Green, that fluoresce when bound to double-stranded DNA, or DNA oligonucleotide sequence-specific fluorescent probes, such as hydrolysis (TaqMan) probes and molecular beacons. Probes bind specifically to DNA target sequences within the amplicon and use the principle of Frster Resonance Energy Transfer (FRET) to generate fluorescence via the coupling of a fluorescent molecule on one end and a quencher at the other end. For both fluorescent dyes and probes, as the number of copies of the target DNA increases, the fluorescence level increases proportionally, allowing real-time quantification of the amplification with reference to standards containing known copy numbers (Figure 3).

qPCR uses specialized thermal cyclers equipped with fluorescent detection systems that monitor the fluorescent signal as the amplification occurs.

Figure 3: Example qPCR amplification plot and standard curve used to enable quantification of copy number in unknown samples.

Reverse transcription (RT) -PCR and RT-qPCR are two commonly used PCR variants enabling gene transcription analysis and quantification of viral RNA, both in clinical and research settings.

RT is the process of making cDNA from single-stranded template RNA3 and is consequently also called first-strand cDNA synthesis. The first step of RT-PCR is to synthesize a DNA/RNA hybrid between the RNA template and a DNA oligonucleotide primer. The reverse transcriptase enzyme that catalyzes this reaction has RNase activity that then degrades the RNA portion of the hybrid. Subsequently, a single-stranded DNA molecule is synthesized by the DNA polymerase activity of the reverse transcriptase. High purity and quality starting RNA are essential for a successful RT-PCR.

RT-PCR can be performed following two approaches: one-step RT-PCR and two-step RT-PCR. In the first case, the RT reaction and the PCR reaction occur in the same tube, while in the two-step RT-PCR, the two reactions are separate and performed sequentially.

The reverse transcription described above often serves as the first step in qPCR too, quantifying RNA in biological samples (either RNA transcripts or derived from viral RNA genomes).

As with RT-PCR, there are two approaches for quantifying RNA by RT-qPCR: one-step RT-qPCR and two-step RT-qPCR. In both cases, RNA is first reverse-transcribed into cDNA, which is used as the template for qPCR amplification. In the two-step method, the reverse transcription and the qPCR amplification occur sequentially as two separate experiments. In the one-step method, RT and qPCR are performed in the same tube.

Digital PCR (dPCR) is another adaptation of the original PCR protocol.4 Like qPCR, dPCR technology uses DNA polymerase to amplify target DNA from a complex sample using a primer set and probes. The main difference, though, lies in the partitioning of the PCR reactions and data acquisition at the end.

dPCR and ddPCR are based on the concept of limiting dilutions. The PCR reaction is split into large numbers of nanoliter-sized sub-reactions (partitions). The PCR amplification is carried out within each droplet. Following PCR, each droplet is analyzed with Poisson statistics to determine the percentage of PCR-positive droplets in the original sample. Some partitions may contain one or more copies of the target, while others may contain no target sequences. Therefore, partitions classify either as positive (target detected) or negative (target not detected), providing the basis for a digital output format.

ddPCR is a recent technology that became available in 2011.5 ddPCR utilizes a water-oil emulsion to form the partitions that separate the template DNA molecules. The droplets essentially serve as individual test tubes in which the PCR reaction takes place.

The recent development of microfluidic handling systems with microchannels and microchambers has paved the way for a range of practical applications, including the amplification of DNA via PCR on microfluidic chips.

PCR performed on a chip benefits from microfluidics advantages in speed, sensitivity and low consumption of reagents. These features make microfluidic PCR particularly appealing for point-of-care testing, for example, for diagnostics applications. From a practical point of view, the sample flows through a microfluidic channel, repeatedly passing the three temperature zones reflecting the different steps of PCR. It takes just 90 seconds for a 10 L sample to perform 20 PCR cycles.6 The subsequent analysis can then be easily carried out off-chip.

The different PCR approaches all have advantages and disadvantages that impact the applications to which they are suited 7. These are summarized in Table 1.

Approach

Advantages

Limitations

PCR

Easiest PCR to perform

Low cost of equipment and reagents

Several downstream applications (e.g., cloning)

Results are only qualitative

Requires post-amplification analyses that increase time and risk of error

Products may need to be confirmed by sequencing

qPCR

Produces quantitative results

Probe use can ensure high specificity

High analytical sensitivity

Low turnaround time

Eliminates requirements for post-amplification analysis

Requires more expensive reagents and equipment

Less flexibility in primer and probe selection

Less amenable to other downstream product confirmation analyses (such as sequencing) due to the small length of the amplicon

Not suitable for some downstream applications such as cloning

RT-PCR and RT-qPCR

Can be used with all RNA types

RNA is prone to degradation

The RT step may increase the time and potential for contamination

dPCR and ddPCR

Fast

No DNA purification step

Provides absolute quantification

Increased sensitivity for detecting the target in limited clinical samples

Highly scalable

Costly

Based on several statistical assumptions

Microfluidic PCR

Accelerated PCR process

Reduced reagent consumption

Can be adapted for high throughput

Portable device for point-of-care applications

Allows single-cell analysis

Still very new technology

Requires extensive sample preparation to remove debris and unwanted compounds

Restricted choice of materials for the microfluidic device due to high temperatures

Table 1: Key advantages and disadvantages of different PCR approaches.

PCR has become an indispensable tool in modern molecular biology and has completely transformed scientific research. The technique has also opened up the investigation of cellular and molecular processes to those outside the field of molecular biology and consequently also finds utility by scientists in many disciplines.

Whilst PCR is itself a powerful standalone technique, it has also been incorporated into wider techniques, such as cloning and sequencing, as one small but important part of these workflows.

Research applications of PCR include:

Gene transcription -PCR can examine variations in gene transcription among cell types, tissues and organisms at a specific time point. In this process, RNA is isolated from samples of interest, and reverse-transcribed into cDNA. The original levels of RNA for a specific gene can then be quantified from the amount of cDNA amplified in PCR.Genotyping -PCR can detect sequence variations in alleles of specific cells or organisms. A common example is the genotyping of transgenic organisms, such as knock-out and knock-in mice. In this application, primers are designed to amplify either a transgene portion (in a transgenic animal) or the mutation (in a mutant animal).Cloning and mutagenesis- PCR cloning is a widely used technique where double-stranded DNA fragments amplified by PCR are inserted into vectors (e.g., gDNA, cDNA, plasmid DNA). This for example, enables the creation of bacterial strains from which genetic material has been deleted or inserted. Site-directed mutagenesis can also be used to introduce point mutations via cloning. This often employs a technique known as recombinant PCR, in which overlapping primers are specifically designed to incorporate base substitutions (Figure 4). This technique can also be used to create novel gene fusions.

Figure 4: Diagram depicting an example of recombinant PCR.Sequencing- PCR can be used to enrich template DNA for sequencing. The type of PCR recommended for the preparation of sequencing templates is called high-fidelity PCR and is able to maintain DNA sequence accuracy. In Sanger sequencing, PCR-amplified fragments are then purified and run in a sequencing reaction. In next-generation sequencing (NGS), PCR is used at the library preparation stage, where DNA samples are enriched by PCR to increase the starting quantity and tagged with sequencing adaptors to allow multiplexing. Bridge PCR is also an important part of the second-generation NGS sequencing process.Both as an independent technique and as a workhorse within other methods, PCR has transformed a range of disciplines. These include:

Genetic research- PCR is used in most laboratories worldwide. One of the most common applications is gene transcription analysis9, aimed at evaluating the presence or abundance of particular gene transcripts. It is a powerful technique in manipulating the genetic sequence of organisms animal, plant and microbe - through cloning. This enables genes or sections of genes to be inserted, deleted or mutated to engineer in genetic markers alter phenotypes, elucidate gene functions and develop vaccines to name but a few. In genotyping, PCR can be used to detect sequence variations in alleles in specific cells or organisms. Its use isnt restricted to humans either. Genotyping plants in agriculture assists plant breeders in selecting, refining, and improving their breeding stock. PCR is also the first step to enrich sequencing samples, as discussed above. For example, most mapping techniques in the Human Genome Project (HGP) relied on PCR.Medicine and biomedical research- PCR is used in a host of medical applications, from diagnostic testing for disease-associated genetic mutations, to the identification of infectious agents. Another great example of PCR use in the medical realm is prenatal genetic testing. Prenatal genetic testing through PCR can identify chromosome abnormalities and genetic mutations in the fetus, giving parents-to-be important information about whether their baby has certain genetic disorders. PCR can also be used as a preimplantation genetic diagnosis tool to screen embryos for in vitro fertilization (IVF) procedures.Forensic science- Our unique genetic fingerprints mean that PCR can be instrumental in both paternity testing and forensic investigations to pinpoint samples' sources. Small DNA samples isolated from a crime scene can be compared with a DNA database or with suspects' DNA, for example. These procedures have really changed the way police investigations are carried out. Authenticity testing also makes use of PCR genetic markers, for example, to determine the species from which meat is derived. Molecular archaeology too utilizes PCR to amplify DNA from archaeological remains.Environmental microbiology and food safety- Detection of pathogens by PCR, not only in patients' samples but also in matrices like food or water, can be vital in diagnosing and preventing infectious disease.PCR is the benchmark technology for detecting nucleic acids in every area, from biomedical research to forensic applications. Kary Mullis's idea, written on the back of a receipt on the side of the road, turned out to be a revolutionary one.

References1. Chien A, Edgar DB, Trela JM. Deoxyribonucleic acid polymerase from the extreme thermophile Thermus aquaticus. J Bacteriol 1976;127(3):1550-57 doi: 10.1128/JB.127.3.1550-1557.1976

2. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230(4732):1350 doi: 10.1126/science.2999980

3. Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HRH. Basic principles of real-time quantitative PCR. Expert Review of Molecular Diagnostics 2005;5(2):209-19 doi: 10.1586/14737159.5.2.209

4. Bachman J. Chapter Two - Reverse-Transcription PCR (RT-PCR). In: Lorsch J, ed. Methods in Enzymology: Academic Press, 2013:67-74. doi : 10.1016/B978-0-12-420037-1.00002-6

5. Morley AA. Digital PCR: A brief history. Biomol Detect Quantif 2014;1(1):1-2 doi: 10.1016/j.bdq.2014.06.001

6. Taylor SC, Laperriere G, Germain H. Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Scientific Reports 2017;7(1):2409 doi: 10.1038/s41598-017-02217-x

7. Ahrberg CD, Manz A, Chung BG. Polymerase chain reaction in microfluidic devices. Lab on a Chip 2016;16(20):3866-84 doi: 10.1039/C6LC00984K

8. Garibyan L, Avashia N. Polymerase chain reaction. J Invest Dermatol 2013;133(3):1-4 doi: 10.1038/jid.2013.1

9. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. BioTechniques 2008;44(5):619-26 doi: 10.2144/000112776

More here:
An Introduction to PCR - Technology Networks

Read More...

22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with…

February 14th, 2021 7:10 pm

WILLIAMSVILLE, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it has developed and launched a new, cutting-edge technology platform that will enable the Company and its strategic partners to quickly identify and incorporate commercially valuable traits of hemp/cannabis plants to create new, stable hemp/cannabis lines. The platform incorporates a suite of proprietary molecular tools and a large library of genomic markers and gene-trait correlations. The platform was developed in collaboration with researchers at KeyGene, a global leader in plant research involving high-value genetic traits and increased crop yields.

This is a major breakthrough. Quickly and easily identifying the genes responsible for specific traits in a plant is a powerful tool for 22nd Century Group and the hemp/cannabis industry as a whole, said James A. Mish, chief executive officer of 22nd Century Group. That is why we are even now beginning discussions to license this platform to strategic partners to help them improve their plant breeding techniques and to optimize their hemp/cannabis cultivars. We continue to make great advancements through our partnership with KeyGene, and this newly developed molecular breeding platform has the potential to result in exponential growth for the Companys revenues and create new value opportunities for our stakeholders, including shareholders.

Using traditional breeding techniques, it typically takes at least eight to ten years to develop new varieties of hemp/cannabis plants that consistently express important traits, said Juan Sanchez Tamburrino, Ph.D., vice president of research and development at 22nd Century Group. Our new molecular breeding platform can dramatically reduce our development time for new high-value varieties of hemp/cannabis and allows 22nd Century scientists to identify plant lines that carry high levels of major therapeutic cannabinoids, such as cannabidiol (CBD), cannabichromene (CBC), and other minor therapeutic cannabinoids, like cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV).

Demonstrating how this technology can be used, 22nd Century and KeyGene scientists can now accelerate the selection of specific traits yielding novel cannabinoid profiles. For example, the team was able to select specific markers that predict the gender of hemp/cannabis plants with an astounding 99.6% accuracy.

Using this new breeding technology, 22nd Century has already characterized millions of high-value single nucleotide polymorphisms (SNPs). SNPs are molecular markers or guideposts within a plants genome that indicate important variations in Deoxyribonucleic acid (DNA) sequences. Targeting these newly identified SNPs, 22nd Century was able to locate and isolate specific sections of genetic code from genome assemblies present in the Companys state-of-the-art hemp/cannabis bioinformatics database. 22nd Centurys bioinformatics database continues to grow and already contains hundreds of hemp/cannabis genomes and thousands expression datapoints across a wide array of hemp/cannabis varieties and phenotypes. The ability to identify specific genetic variations allows researchers to isolate high-value traits, like increased CBD or tetrahydrocannabinol (THC) production, and then introduce those traits in new plant lines using modern plant breeding techniques, including trait tracking using molecular marker profiles and the Companys proprietary accelerated breeding pipeline.

Since reporting third quarter earnings, 22nd Century has refocused its hemp/cannabis strategy to target the upstream segments of the cannabinoid value chain, in particular, in the areas of plant biotechnology research, gene modification and engineering, modern plant breeding and development, and extraction. The Company intends to build upon its core strengths in the plant science and ingredient value chain and is in advanced discussions with operational partners that will enable it to offer comprehensive commercial breeding, cultivation, and extract purification services utilizing its proprietary hemp/cannabis plants in development. The Company will continue to focus on and ensure the accelerated delivery of valuable, commercial plant lines and technology, and related intellectual property for the life science, consumer product, and pharmaceutical markets.

About 22nd Century Group,Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Centurys primary mission in tobacco is to reduce the harm caused by smoking through the Companys proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes. The Companys primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

Learn more atxxiicentury.com, on Twitter@_xxiicenturyand onLinkedIn.

Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as anticipate, believe, consider, continue, could, estimate, expect, explore, foresee, goal, guidance, intend, likely, may, plan, potential, predict, preliminary, probable, project, promising, seek, should, will, would, and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in Risk Factors in the Companys Annual Report on Form 10-K filed on March 11, 2020 and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com

Read the rest here:
22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with...

Read More...

Science Talk – Evolution, cancer and coronavirus how biology’s ‘Theory of Everything’ is key to fighting cancer and global pandemics – The Institute…

February 14th, 2021 7:10 pm

Image: Charles Darwin's Tree of Life

The 12th of February 2021 marks Sir Charles Darwins 212th birthday a day when biologists and many others remember one of the greatest scientists to have ever lived, whose work and theories transformed biology and the world.

Sir Charles Darwins observations that species adapt through variations passed on from one generation to the next is the basis of modern biology a deceptively simple rule that accounts for all of the variation we see in the natural world.

All organisms, big and small, evolve over time to adapt to the environments they inhabit and the same is true for cancer. Understanding evolution is key to the study of cancer and to developing new treatments for the disease. Its also pretty important when it comes to fighting viruses like Covid-19.

This Darwin Day, we spoke to two of our researchers working in the ICRs Centre for Evolution and Cancer, who are building on Darwins theories of evolution to explore new ways to treat cancer.

The ICR's Centre for Evolution and Cancer aims to apply Charles Darwins principle of natural selection to our understanding of why we develop cancer and why it is so difficult to treat.

Find out more

Dr Alejandra Bruna is leader of the Preclinical Modelling of Paediatric Cancer Evolution Team, and she is trying to find the evolutionary components that drive cancer in children.

The ICR is an internationally leading research centre in the study of cancer in children, and Dr Brunas work focuses on neuroblastoma, the most commonly fatal solid tumour in children, among other solid paediatric cancers.

One of the main features of cancer is genomic instability, with most adult cancers displaying high levels of mutations which cancer is able to exploit for survival.

Following Darwins theories of Natural Selection, each mutation could potentially help a cancer cell adapt to its environment better to survive, with beneficial adaptations being passed on through cell division.

Preventing or targeting mutations is an important way to treat cancer, but childhood cancers often display very few mutations, and researchers like Dr Bruna think that there may be different evolutionary forces at work.

Her research is looking at epigenetic changes in childhood cancer cells changes to genes that arent caused by mutations, but that can turn genes on and off in cells.

Her team are investigating whether these epigenetic changes could be the driver for how neuroblastoma cells evolve, which could explain how cancer cells with very few mutations can adapt and develop resistance to treatments.

Dr Bruna says, If non-genetic evolution plays a role in resistance to therapy in paediatric tumours, then we should be trying to focus on finding treatments that target these non-genetic events.

She is using a technique to barcode cells in samples of neuroblastoma, to trace cell dynamics and epigenetic changes over time, which may identify the triggers for mutations that lead to resistance to treatment.

Finding the epigenetic changes that lead to resistance in neuroblastoma will be a challenge, but if they can show that they happen before mutations occur, this incredibly exciting discovery could open up new avenues for treatment for childhood cancers.

The ICRs Centre for Evolution and Cancer has developed sophisticated computer simulations to model how tumours evolve over time, but recreating the complexity of the disease seen in humans is still a huge challenge.

Diseases like prostate cancer are caused by hundreds of mutations that build up in cancer cells, so to understand how prostate cancer might evolve in patients, tests that help reflect this diversity are needed.

Dr Marco Bezzi leads the Tumour Functional Heterogeneity Team at the ICR, and he is using lab-grown mini-tumours called tumour organoids that more closely resemble cancer as its seen in the clinic, to better understand how prostate cancer evolves.

Dr Bezzi says, The ICRs mathematical modelling is really strong, and you can really follow how tumours develop through evolutionary principles. My research takes a very wet lab approach to complement this, by recreating the heterogeneity and selective pressures that cancer faces. We can then track this experimentally to understand how tumours evolve.

His lab generates biobanks of cancer organoids they use to mix together different mutations and grow tumour organoids with distinct genetic patterns.

These organoids can have several different mutations important to prostate cancer within one tumour, which can be studied in mice to see how these populations evolve.

Like Dr Brunas team, they hope to track how tumours evolve across generations of cancer cells using barcodes, to see which mutations give cells survival advantages and are passed on, and which die out.

Working together with mathematical modelling, ICR scientists can test how simulations of cancer evolution stand up to real-world examples to refine their predictions.

The goal is to use these different tools in the lab to understand how tumours in patients may evolve in response to treatment, so they can suggest new treatments as tumours adapt and help patients survive for longer.

These two examples take very different approaches to cancer evolution, but they show how this fundamental principle of life can be harnessed to learn more about cancer and design better ways to treat the disease.

Image: The ICR's Centre for Cancer Drug Discovery

Dr Bruna and Dr Bezzi have just moved into the ICRs new Centre for Cancer Drug Discovery, where researchers working in cancer evolution benefit from the expertise of their colleagues discovering new cancer drugs.

The building is the first of its kind to host hundreds of scientists from different disciplines under one roof to lead an unprecedented 'Darwinian' drug discovery programme that aims to overcome cancers ability to evolve resistance to drugs and herd it into more treatable forms.

The ultimate aim is to transform cancer into a manageable disease that can be controlled long term and effectively cured.

Dr Bezzi says, As a biotechnologist most of what I do is genetic engineering, so its fantastic to have access to the expertise of my colleagues in drug discovery.

By sharing the same spaces, we can share our expertise and knowledge. I can have those quick conversations about experiments and ask them what might be the best drug for a specific type of disease or for that specific patient. The connection we have to the clinic is amazing and it ensures that my work is studying the right questions to help patients.

In our pioneering Centre for Cancer Drug Discovery, our researchers are now developing a new generation of drugs that will make the difference to the lives of millions of people with cancer.

But we still need your support to help finish equipping the Centre and to continue to fund the exciting work that is now taking place within the building.

Donate now

As the world battles with the coronavirus pandemic, scientists can apply the same evolutionary thinking our researchers use in cancer to overcome Covid-19.

Professor Andrea Sottoriva, Director of the Centre for Evolution and Cancer in the Centre for Cancer Drug Discovery, says: Evolutionary biology is one of the most important theories of biology, in the same way that we have general relativity in physics. The theory of evolution allows us to make sense of the observations we see in biology and medicine more widely, and this is also true for the pandemic.

We understand how viruses evolve through the lens of evolutionary biology and we design new vaccines that combat the evolution of viruses to adapt and survive, like what we regularly see in the flu.

The variants we are now seeing in Covid-19 are evidence of the fundamental mechanisms that drive how all organisms evolve, including cancer.

Not every variation provides a survival advantage to viruses, making viruses more contagious or more resilient, and viruses often need a number of significant changes before vaccines will no longer work, but by studying how they change and evolve, doctors can attempt to get ahead of new variants with improved vaccines, helping curb transmission and save lives.

Dr Bruna said: Just like cancer, viruses are made of genetic material, and so they will evolve adaptations that are beneficial to the virus. But scientists will be expecting this and they are monitoring variations in the virus that are occurring.

With cancer the rules are exactly the same, and our researchers are coming up with new ways to model the disease's evolution and to find the triggers that help cancer develop.

And so, despite the death of Sir Charles Darwin more than 130 years ago, the impact of his work lives on and acts as inspiration for researchers around the world, and will continue to do so for generations to come.

Here is the original post:
Science Talk - Evolution, cancer and coronavirus how biology's 'Theory of Everything' is key to fighting cancer and global pandemics - The Institute...

Read More...

Three ayurvedic concoctions get scientific validation for treating rheumatoid arthritis – Free Press Journal

February 14th, 2021 7:08 pm

She said the study was conducted in four phases in rats after inducing rheumatoid arthritis and the treatment duration was based on standard protocol. "Severity of pain and inflammation associated with rheumatoid arthritis were decided by the infiltration of so many pro-inflammatory cytokines, lymphocytes, oxidants etc. By this study we were able to find that kashayams exerted therapeutic efficacy in the management of rheumatoid arthritis by regulating pro anti-inflammatory cytokines balance, increasing antioxidant level and by immune modulation," said Aswathy.

The study team that was guided by A. Helen, Professor and Mentor, has published their work in the international peer reviewed Journal of Ayurveda and integrative medicine and two papers are under review. The highlight of the study is that while all these three kashayams are available in the market there was no scientific validation, which the study team has been able to do.

The team instead of relying on the readily available kashayams, decided to make their own under the guidance of Ayurveda physician Sukumara Varier of Kottakal Arya Vaidyasala. The team prepared the decoction from 28 different forms of herbs and the major difference was they did not add any substance, which is added to increase the shelf life.

With regard to the outcome, Aswathy said "our attempt was to give better hope to patients suffering from rheumatoid arthritis besides a vehicle to enrich traditional knowledge with well documented scientific background for the sake of mankind."

Go here to read the rest:
Three ayurvedic concoctions get scientific validation for treating rheumatoid arthritis - Free Press Journal

Read More...

COVID Long-Haulers Find Relief Among Fellow Sufferers on Road to Recovery – WCCO | CBS Minnesota

February 14th, 2021 7:08 pm

SAN FRANCISCO (KPIX) Around California and the Bay Area youll find them: members of a club that no one wants to join. These are patients who experience lingering misery after they no longer test positive for SARS-CoV-2. Theyre known as the long-haulers.

About 10 percent of patients whove had an initial COVID-19 infection will go on to not fully recover, said UCSF neurologist Dr. Juliet Morgan.

It puzzled a lot of us, said Dr. Meghan Jobson, palliative care Fellow at UCSF.

KPIX met two long-haulers: retired former banker Bruce Wheeler and Carla, who is a first responder. Carla asked us not to use her last name.

It felt very lonely and, after a while, you wonder: is this in my head? Wheeler said.

When Carla first noticed the symptoms of her long-haul syndrome, she was worried.

I dont think Im going to be OK, she remembered thinking.

Both were infected last year and felt awful. The infections went away but their brush with the novel coronavirus was far from over. For months, they continue to suffer baffling, debilitating health conditions.

I know what its like to be really tired but this was different, explained Carla.

Carla used to bicycle hundreds of miles and run marathons. Today, she feels extraordinary fatigue, shortness of breath and a terrible, systemic pain.

You know when you cut yourself and you put alcohol in there and you know it burns? she asked. It was similar to that but all over.

Wheeler was an active hiker but he now reports fatigue, persistent shortness of breath, nausea, brain fog and destabilizing headaches.

Many days I get up at 8 oclock in the morning and, at 10 oclock, Im back in bed because my headache is pounding away, he said.

The symptoms for long-haul syndrome vary but can also include a loss of the sense of smell and taste, as well as hair loss.

Theres also a report of patients developing serious inflammatory conditions. Preliminary data indicate that some asymptomatic college athletes developed an inflammatory heart condition.

Whats frustrating is that the syndrome is not well understood. Family, friends, co-workers and colleague often express disbelief at the constellation of symptoms, questioning if the patient is actually sick. Often, patients are mistakenly prescribed anti-anxiety medicine, even anti-depressants.

There just werent answers, Wheeler said.

I felt hopeless, said Carla.

Their situation reached the attention of Dr. Morgan and Dr. Jobson. They both specialize in chronic conditions that impact quality of life and they have expertise in integrative medicine.

What we had been hearing from multiple survivors of COVID-19 is that they didnt feel heard, explained Dr. Jobson.

The cause for the syndrome remains unclear although it may involve an overreactive immune or inflammatory response. And, while older people appear more likely to get it, young people are not immune.

We will see plenty of very young patients in their twenties and thirties who have this COVID long-haul syndrome who continue to suffer, Dr. Morgan said.

The doctors established an online COVID support group: the first of its kind in the nation. Meetings are packed.

There is strength in survivorship, explained Dr. Jobson.

During group sessions, patients share their stories. The doctors answer questions, address fringe treatments and provide expertise in how to manage symptoms.

Shortness of breath, the fatigue we know a lot of the data and literature surrounding these things, Dr. Jobson said.

Instruction is given in ways to relax such as mindfulness and meditation.

Mindfulness is actually pretty powerful and potent medicine. We know in studies that it can reduce markers of stress like cortisol. It can reduce inflammatory markers like IL-6. Dr. Morgan explained.

Bruce Wheeler and Carla told KPIX the online support and help has already provided a great benefit.

Literally in the last two weeks, I began to see improvement on the headache front, Wheeler said.

Instead of doing it every once in a while, now I do it every day, every night, Carla added.

They also learn from each other what strategies work, what doesnt and theyve been inspired by others.

I am really impressed by Carlas strength and that she saw the silver lining even when it was a really bad, bad day, Bruce commented.

Carla did lose her hair. When Bruce saw her online, Carla recounted how he said just the right thing.

He took it upon himself to say You know what Carla, it actually looks pretty good on you, she smiled.

As for the doctors, theyve learned quite a lot from their patients: curiosity, resilience, respect and tenacity.

Theyre showing us what it looks like to ask for help, Dr. Morgan said.

We encourage other people in other areas of the country to start support groups, Dr. Jobson added.

There are other extraordinary COVID long-haul syndrome support groups, such as Survivor Corps and Body Politic.

The UCSF group was so successful and helpful to the long-haulers involved, they asked Dr. Jobson and Dr. Morgan to extend it. Now a new one is set to begin this spring. There is no cost to patients.

The rest is here:
COVID Long-Haulers Find Relief Among Fellow Sufferers on Road to Recovery - WCCO | CBS Minnesota

Read More...

Health Coaching Market Increasing Demand with New Technologies by 2027 ExpertRating, Duke Integrative Medicine, National Society of Health Coaches,…

February 14th, 2021 7:08 pm

Health Coaching Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report.

Health Coaching is a novel approach to manage health and help people for maintaining good health. Health coaching help patient in variety of ways for management of chronic ailments such as diabetes, chronic pain, metabolic syndromes. Health coach is responsible for guiding the patient in dos and donts. The health coach is responsible for setting goals and targets for patients and also evaluating results on timely basis. The applications of health coaching are in, behavioral management, stress management, fitness, chronic ailments etc.

Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00018017/

Health Coaching Market Competition Landscape and Key Developments:

Health Coaching Market Segmental Overview: The report specifically highlights the Health Coaching market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, key players in the market, sales, distribution chain, manufacturing, production, new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

The report specifically highlights the Health Coaching market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, key players in the market, sales, distribution chain, manufacturing, production, new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

To comprehend global Health Coaching market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Our Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Reasons to Buy:

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00018017/

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

Continue reading here:
Health Coaching Market Increasing Demand with New Technologies by 2027 ExpertRating, Duke Integrative Medicine, National Society of Health Coaches,...

Read More...

Apprenticeships are the catalyst for opportunity – Crain’s Chicago Business

February 14th, 2021 7:08 pm

To build a diverse workforce that reflects the country and matches emerging employer needs, we must increase efforts to support students from high school through college with targeted training, on-the-job paid work experience, individualized supports, and career counseling.

Baker's experience highlights a key ingredient: "What really made it work for me was that everyone was committed to one common goal in creating a pathway for success."

Obtaining a four-year college degree is not essential for all students. In Illinois, 52 percent of jobs require education and training beyond high school, but not a B.A. degree. These high-demand fields include health care, medical technology and advanced manufacturing.

At One Million Degrees, our focus is on providing a range of supports to Chicago-area community college students and serving as a connector to employers. Across the state, 60 percent of public college students attend community colleges. Many, like Baker, are the first in their family to attend college and are working full-time jobs and supporting their families.

We are seeing employers across industries partner with educators and students to build on-ramps to in-demand jobs, especially through new apprenticeship programs. There's growing recognition that these programs can help address long-standing underrepresentation in lucrative fields among Blacks, Latinx and women, by providing both access and wraparound support.

Those supports, from stipends and transportation vouchers to child care and counseling must be aligned with the specific needs of each student. "Each individual is unique and needs different supports," says Baker, who found personal contacts for emotional support especially useful over the past year.

Chicago and the state of Illinois are leading the way. MAPP is but one of several new promising programs. Supported by health care providers Rush University Medical Center, Ann & Robert H. Lurie Children's Hospital of Chicago, NorthShore University HealthSystem, University of Chicago Medicine and Sinai Health System, plus West Side United, One Million Degrees and Malcolm X College, the program is designed to help students advance their careers in the health care sector.

The Chicago Apprenticeship Network has become a national model, with one of its founders, Aon, taking the program to six new cities. The strength of the Chicago program is its array of partners40 companies across 16 industries, City Colleges of Chicago and One Million Degreesas it plans to develop 1,000 apprenticeships.

One Million Degrees is also providing mentors to support Career Launch Chicago, an effort by the city of Chicago, Chicago Public Schools and City Colleges to provide high school students entering college with paid work experiences.

Research from the University of Chicago Inclusive Economy Lab on the impact of our support program for community college students shows increases in college enrollment, full-time enrollment and persistence. Our own analysis shows that our support of college apprentices contributes to high retention rates: 98 percent in our collaboration with Aon and 94 percent with MAPP.

We should be encouraged by the momentum around combining training and education opportunities. The state of Illinois is investing in apprenticeships across the state. President Joe Biden pledged during his campaign to make a $50 billion investment in workforce training, including community college business partnerships and apprenticeships.

Apprenticeships can be a bipartisan way of directing increased education and training support to closing skills gaps and should focus on expanding beyond the trades, where they are now concentrated, according to a new report from Brookings.

As Baker tells us, apprenticeships are the catalyst for opportunity. "For years, I kept telling myself that next semester I'd go back to school. MAPP opened the door for me to pursue my dream."

Paige Ponder is chief executive officer of One Million Degrees, a nonprofit providing support to community college students to help them succeed.

Here is the original post:
Apprenticeships are the catalyst for opportunity - Crain's Chicago Business

Read More...

Tuning the circadian clock, boosting rhythms may be key to future treatments and medicines – Newswise

February 14th, 2021 7:08 pm

Newswise Irvine, CA February 11, 2021 Subconsciously, our bodies keep time for us through an ancient means the circadian clock. A new University of California, Irvine-led article reviews how the clock controls various aspects of homeostasis, and how organs coordinate their function over the course of a day.

What is fascinating is that nearly every cell that makes up our organs has its own clock, and thus timing is a crucial aspect of biology, said Kevin B. Koronowski, PhD, lead author and a postdoctoral fellow in Biological Chemistry at the UCI School of Medicine. Understanding how daily timing is integrated with function across organs has implications for human health, as disruption of the clock and circadian rhythms can be both a cause and effect of diseases from diabetes to cancer.

The circadian clock generates a ~24 hour rhythm that controls behavior, hormones, the immune system and metabolism. Using human cells and mice, researchers from the Paolo Sassone-Corsi Laboratory at UCI's Center for Epigenetics and Metabolism aim to uncover the physiological circuits, for example between the brain and liver, whereby biological clocks achieve coherence. Their work, titled, Communicating clocks shape circadian homeostasis, was published today in Science.

Circadian clocks align internal processes with external time, which enables diverse lifeforms to anticipate daily environmental changes such as the light-dark cycle. In complex organisms, clock function starts with the genetically encoded molecular clock or oscillator within each cell and builds upward anatomically into an organism-wide system. Circadian misalignment, often imposed in modern society, can disrupt this system and induce adverse effects on health if prolonged.

Strategies to tune our clocks and boost rhythms have been promising in pre-clinical studies, which illustrates the importance of unraveling this aspect of our biology and unlocking the potential it holds for treatments and medicines of the future, said Koronowski.

Without electrical light, high-speed travel, constant food availability and around the clock work-life schedules, our ancestors clocks were in constant harmony with the environment. However, due to these pressures of modern society, aligning our internal time with geophysical time has become a challenge in todays world. Chronic misalignment when eating and sleeping patterns conflict with the natural light-dark cycle is associated with an increased risk of metabolic syndrome, cardiovascular disease, neurological conditions, and cancer. A large portion of the global workforce has atypical hours and may be particularly vulnerable.

It has become urgent that we uncover the molecular underpinnings of the relationship between the circadian clock and disease, explained Koronowski. Deciphering the means by which clocks communicate across metabolic organs has the potential to transform our understanding of metabolism, and it may hold therapeutic promise for innovative, noninvasive strategies to promote health.

This work is dedicated to the memory of Paolo Sassone-Corsi (19562020), a great scientist, mentor, and human. It was funded in part by the National Institutes of Health, Novo Nordisk Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

###

Read the rest here:
Tuning the circadian clock, boosting rhythms may be key to future treatments and medicines - Newswise

Read More...

Global Alternative Healthcare Providers Market Outlook for Major Applications/end Users, Consumption, Share and Growth Rate 2023 KSU | The Sentinel…

February 14th, 2021 7:08 pm

Global Alternative Healthcare Providers Market: Overview

Practice of complementary and alternative medicine comprises many different areas of medicines. In addition to that, it is possible that many parts of one field will overlap with another in another area. A case in point is acupuncture, which finds use in both alternative and conventional medicine. Alternative medicine refers to those medical treatments that find utilization instead of conventional therapies. Few people call them complimentary or integrative medicine. Many people make use of alternative therapies so as to make them deal and feel better with diseases like cancer. In this type of treatment, how one feels is an important part in how you cope up with the disease.

Many of the alternative healthcare therapies focus on the reduction of and relaxation from stress. These therapies increase general sense of wellbeing, relieve anxiety, and calm ones emotions. Several doctors, researchers, and nurses have exhibited interest in the concept of positive emotions making improvements in ones health. These factors are estimated to propel the global alternative healthcare providers market toward growth over the forecast tenure.

This report on the global alternative healthcare providers market takes a closer look at the key changes in consumer preferences and those preferences affect the growth of market. The insights offered into the report assist investors and the market players in making an informed choice about the market. The information shared in the report will help the stakeholders formulate strategies accordingly

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6017

Global Alternative Healthcare Providers Market: Trends and Opportunities

Growing Faith and Awareness in Alternative Medicines Escalates Demand

The global alternative healthcare providers market has prospered on the back of the growing interest of people in such forms of medicines. Growing preference for alternative medicines has resulted from peoples increasing willingness to experiment with alternative medicines.

Alternative healthcare providers make an offering of a wide variety of products and practices and medical and healthcare systems that are used by patients sans medical supervision. Usually, alternative medicines and treatments are not availed by the people suffering from various chronic diseases like diabetes, cancer, liver disease, and osteoporosis. However, there has been a slight change in attitude, a few patients suffering from such chronic diseases are opting for alternative medicines. Such changes in the behavior pattern of patients are expected to spearhead the expansion of the global alternative healthcare providers market in years to come.

Yoga, ayurveda, homeopathic medicines, acupuncture, and unani medicines are some of the types of alternative medicines. The global alternative healthcare providers market is likely to be driven by growing adoption and use of various natural wellness and supplements medicine. In addition to that favorable government initiatives in certain countries, particularly in the Asia Pacific, are expected to create substantial opportunities of growth for the global alternative healthcare providers market over the period of review.

Request for Analysis of COVID19 Impact on Alternative Healthcare Providers Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=6017

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Alternative Healthcare Providers market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Alternative Healthcare Providers market.

Global Alternative Healthcare Providers Market: Competitive Landscape

Key players profiled in the global alternative healthcare providers market are The Healing Company, Columbia Nutritional Inc., Pure encapsulations, Inc., John Schumachers Unity Woods Yoga Center, Pure encapsulations, Inc., and Allen Laboratories Ltd.

Buy Alternative Healthcare Providers Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=6017&ltype=S

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/single-handed-surgical-suturing-devices-in-surgical-equipment-market-advance-capabilities-of-healthcare-facilities-market-to-reach-valuation-of-us-14-8-bn-by-2030-end-301125408.html

https://www.prnewswire.co.uk/news-releases/acute-lymphoblastic-leukemia-market-to-reach-usd-3-3-billion-by-2026-rise-in-number-of-new-product-approvals-and-clinical-trials-to-drive-the-market-tmr-807181630.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website:https://www.transparencymarketresearch.com/

The rest is here:
Global Alternative Healthcare Providers Market Outlook for Major Applications/end Users, Consumption, Share and Growth Rate 2023 KSU | The Sentinel...

Read More...

Page 215«..1020..214215216217..220230..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick